Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16792295 | 0.98 | HRH2 (0.33) | HRH2HRH3 | |
| SCHEMBL15415724 | 0.92 | — | — | |
| SCHEMBL19410875 | 0.77 | TDO2 (0.35) | HRH2HRH3 | |
| SCHEMBL15540826 | 0.76 | — | — | |
| SCHEMBL15415389 | 0.74 | PDE10A (0.32) | — | |
| SCHEMBL15415548 | 0.73 | PSMB5 (0.36) | — | |
| SCHEMBL19410885 | 0.73 | TDO2 (0.32) | — | |
| SCHEMBL15414794 | 0.73 | — | — | |
| SCHEMBL15414801 | 0.72 | ACMSD (0.38) | — | |
| SCHEMBL15415783 | 0.70 | ACMSD (0.40) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9550737-B2 | TNF -α modulating benzimidazoles | UCB BIOPHARMA SPRL (BE) | 2017-01-24 | — | — | US | disclosed |
| US-9475820-B2 | Substituted imidazo[1,2-a]pyrazines as TNF activity modulators | UCB BIOPHARMA SPRL (BE) | 2016-10-25 | — | — | US | disclosed |
| US-20150191482-A1 | Imidazopyrazine Derivatives as Modulators of TNF Activity | UCB BIOPHARMA SPRL (BE) | 2015-07-09 | — | — | US | disclosed |
| US-20150152065-A1 | TNF -Alpha Modulating Benzimidazoles | UCB BIOPHARMA SPRL (BE) | 2015-06-04 | — | — | US | disclosed |
| EP-2872511-A1 | IMIDAZOPYRAZINE DERIVATIVES AS MODULATORS OF TNF ACTIVITY | UCB Biopharma SPRL (BE) | 2015-05-20 | — | — | EP | disclosed |
| EP-2858983-A1 | TNF -ALPHA MODULATING BENZIMIDAZOLES | UCB Biopharma SPRL (BE) | 2015-04-15 | — | — | EP | disclosed |
| WO-2014009296-A1 | IMIDAZOPYRAZINE DERIVATIVES AS MODULATORS OF TNF ACTIVITY | UCB PHARMA S.A. (BE) | 2014-01-16 | — | — | WO | disclosed |
| WO-2013186229-A1 | TNF -ALPHA MODULATING BENZIMIDAZOLES | UCB PHARMA S.A. (BE) | 2013-12-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150152065-A1 | TNF -Alpha Modulating Benzimidazoles | TNF, TNFRSF1A, NFKBIA | HRH2 1541/4885HRH3 2986/4885 |
| US-20150191482-A1 | Imidazopyrazine Derivatives as Modulators of TNF Activity | TNF, TNFRSF1A, NFKBIA | HRH2 1170/4885HRH3 3416/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.